SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May, 2023.
Commission File Number: 001-40530
GH Research PLC
(Exact name of registrant as specified in its charter)
Joshua Dawson House
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
|Form 20-F||Form 40-F|
On May 23, 2023, a manuscript titled “A Phase 1/2 Trial to Assess Safety and Efficacy of a Vaporized 5-Methoxy-N,N-Dimethyltryptamine Formulation (GH001) in Patients with Treatment-Resistant Depression” was accepted for publication in Frontiers in Psychiatry. The manuscript describes the results of our completed phase 1/2 clinical trial in patients with treatment-resistant depression (GH001-TRD-102, NCT04698603). The abstract is available on the publisher’s website. The final, formatted version of the manuscript will be published in due course.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|GH Research PLC|
|Date: May 25, 2023|
|By:||/s/ Julie Ryan|
|Title:||Vice President, Finance|